AVXL Anavex Life Sciences Corp. - 8-K

Item 8.01.   Other Events.

On March 25, 2026, Anavex Life Sciences Corp. (the “Company”)
issued a press release announcing that it has withdrawn its application for the marketing authorization of blarcamesine in the EU as an
add-on therapy for the treatment of early Alzheimer’s disease in adults, which had been under review by the European Medicines Agency
(EMA).

A copy of the press release is furnished as Exhibit
99.1 and is incorporated herein by reference, including the cautionary statement on forward-looking statements included in the press release.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1

Press Release of the Company dated March 25, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)